The rise in antibiotic resistance is a global health concern that necessitates judicious use of these drugs. This article aims to provide a comprehensive guide to promote rational use of antibiotics in clinical practice.
Antibiotic resistance occurs when bacteria mutate in response to the use of these drugs. It is a natural phenomenon that is accelerated by the misuse and overuse of antibiotics. The consequences of antibiotic resistance are severe, leading to longer hospital stays, higher medical costs, and increased mortality.
Rational antibiotic use involves prescribing the right drug, at the right dose, for the right duration, and at the right time. It is important to make use of diagnostic tests to identify the causative organism and its antibiotic susceptibility. Empirical therapy should be tailored based on local epidemiological data and individual patient factors. Antibiotics should be de-escalated whenever possible, based on culture results.
Antimicrobial stewardship programs (ASPs) are coordinated interventions designed to improve and measure the appropriate use of antimicrobials. They involve a multidisciplinary team that includes infectious disease physicians, pharmacists, microbiologists, and infection control professionals. ASPs have been shown to reduce antibiotic resistance, improve patient outcomes, and decrease healthcare costs.
Education of healthcare professionals and patients is a key component of rational antibiotic use. Healthcare professionals need to be updated about the latest guidelines and resistance patterns. Patients need to be counseled about the importance of adherence to prescribed therapy, the risks of self-medication, and the appropriate use of antibiotics.
Rational use of antibiotics is a collective responsibility that involves healthcare professionals, patients, and policy makers. By adhering to the principles of rational antibiotic use and implementing antimicrobial stewardship programs, we can curb the rise of antibiotic resistance and ensure the longevity of these life-saving drugs.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation